ITL Healthcare SEA has been awarded the 2008 Malaysia Medical Device Distributor of the Year at the Frost & Sullivan Excellence in Healthcare Awards ceremony in Singapore

The 3 years extensions are with: Terumo Penpol - India; Terumo Corporation - Japan; and Terumo Medical Products - China

Appendix 3Y - Change of Director’s Interest Notice

The Directors of ITL are pleased to announce the execution of agreements to acquire the businesses of two Malaysian companies - Inspire Vision Technologies Sdn. Bhd. and Inspire Vision Medical Sdn. Bh

American Red Cross Extends Contract for further two years

Results for announcement to the market, Supplementary Appendix 4D information, Half yearly report.

ITL Healthcare, a member of the ITL Group, today made announcement about its new ethylene oxide steriliser is now in commercial operation.

ITL Healthcare Pty Ltd, a member of ITL Group, is pleased to announce it has signed a two year non-exclusive, preferred supplier agreement with Ramsay Health Care Australia Pty Ltd to provide custom p

On Market Shae Buy-Back

Bill Mobbs Directors Notice of Interest Change

Julian Gosse Directors Notice of Interest Change

Richard England Directors Notice of Interest Change

Roy Rose Directors Notice of Interest Change

New issue announcement, application for quotation of additional securities and agreement.

ITL Annual Report 2007

ITL Limited 2007 Proxy Form

ITL Limited Chairman's Letter

ITL Limited Notice of Meeting

ITL Change of record date for Final Dividend

Company Snapshot ITL Limited (ASX:ITD) 23rd August 2007

Appendix 4E: Preliminary final report for the year ended 30 June 2007

CEO Bill Mobbs buys more ITL shares.

Chairman Julian Gosse buys more ITL shares.

Director Roy Rose buys more ITL Shares.

The Company confirms the forecasted revenue, net profit and EBITDA performance as previously advised in the 6 June 2007 market update.

ITL aITL announces that it has raised $8.32M by way of a placement of 16 million shares at 52c. The placement brings several leading fund managers onto the ITL register.

Medical device and kit manufacturer ITL has raised $8.32 million to fund its Asian growth strategy.

ITL Limited confirms the interim dividend of $0.005 per share.

ITLs R and D TINA Project has been boosted by additional grant funds from the Commonwealth Government R and D Start Programme

Appendix 4D with financial statements - dividend payable.

ITL announces half yearly report and interim dividend.

ITL and Fresenius HemoCare have entered into a cooperation agreement to trial ITLs two new retractable safety needles.

ITL impressive procedure kit facility

ITL Group Limited HY07 Guidance of NPBT $2.1m, EBITDA 2.9m

Healthy gains set up ITL for record result

ITL Advises Market that the un-audited Revenue for the first half to 31st Dec 06 was $20.3M

Appendix 3Y Directors Interest Notice

Appendix 3Y Directors Interest Notice

ITL (ASX:ITD), has received the US Court of Appeals decision on the long running ‘Platypus’ patent infringement case between DSU Medical Corporation Vs ITL & JMS (ITL’s US Distributor).

A new facility to meet a growing demand

ITL (ASX:ITD) is proud to announce that it has gained TGA approval for its new Australian based manufacturing facility at Chelsea Heights, Melbourne.

Appendix 3Y Directors Interest Notice

Appendix 3Y Directors Interest Notice

Appendix 3Y - Change of Directors Interest

FY 07 Guidance of 15% Revenue Growth to $36m

2006 Annual General Meeting – Proxy Votes

ITL Confirms 2006 Record Profit as Revenue Continues to Grow

ITL CEO Mr Bill Mobbs' Presentation for AGM 2006

674,259 ordinary shares have been taken up by ITL Directors under the Dividend Reinvestment Plan

CEO Mr Bill Mobbs and non Executive Director Mr Roy Rose have both lodged Appendix 3Y Notices.

ITL reported to the ASX today that it has no outstanding options.

ITL Limited confirms that the final dividend of $0.01 per share was declared an eligible dividend under the Dividend Reinvestment Plan (DRP) and gives notice that the subscription price for DRP Shares

Bill Mobb's presents an investor update to Boardroom Radio.

ITL Annual General Meeting supporting Documentation

ITL has just released our Annual Report for Financial year 2005/06

Change of Director's Interest - Rose

New issue announcement, application for quotation of additional securities and agreement

ITL (ASX: ITD, www.itl-limited.com) specialises in creating medical devices and procedure kits for global healthcare markets.

Report on ITL's performance in 2006 and summary of business for investors.

ITL is pleased to announce a five year supply agreement with bioMérieux for ITL's new SampLok® Blood Collection Adapter for use with the BacT/ALERT® product line.

William Mobbs: Change of Director's Interest Notice

Roy Rose: Change of Director's Interest Notice

Important figures for 2006, presented by Bill Mobbs, CEO.

Appendix 4E and preliminary Full Year Financial Report

Please find attached our July edition of the ITL Newsletter.

Form 604, has been lodged with the stock exchange today.

ITL wishes to advise the market of an updated guidance for our 2006 financial results.

Blips on the radar that could make it big” The review written by Trevor Hoey says “ its full-year impact along with management’s forecast of organic growth of 20 per cent should mak

Intersuisse’s recommendation is: “The Company is forecast to experience strong sales growth. It generated its first profit on December 2005, we anticipate a NPAT of $2.8m for the fiscal year 2006.

InterFinancial Review of ITL and Interview with ITL's CEO Bill Mobbs

ITL has signed a $6 million (AUD) contract to supply medical equipment to the prestigious Prince Court Medical Centre (PCMC) in Malaysia.

Director Mr Roy Rose has purchased 100.000 ordinary ITL shares

ITL was invited to present at the Citigroup Micro Caps Conference held in Sydney on Tuesday 4 April 2006. This was a great opportunity to showcase our company to over 100 business analysts and invest

ITL has just released the March 2006 version of our Newsletter.

ITL CFO Susan Williams has purchased 500,000 ordinary shares, issued on 13 March 2006

The Australian Financial Review wrote today that ITL is one of the top 10 undervalued stocks. Reporter Trevor Hoey said that ITL was a ‘small firm with big potential.’ ITL was nominated by MMC Asset

ITL is again showing a strong result on the back of consistant growth.

ITL has just released its Appendix 4D Half Yearly Results - February 2006

ITL Investor Presentation February 2006

Half-yearly report six months ended 31 December 2005

New issue announcement, application for quotation of additional securities and agreement

ITL wishes to advise the market that our revenues for the first half to 31st December 2005 were $13.3M this is a 20% increase over the first half of 2004/05 revenues of $11.1M.

ITL today announces it has completed the acquisition of leading Malaysian healthcare company, Heal Marketing Sdn Bhd.

Change of Director's Interest Notice: Julian Gosse

Change of Director's Interest Notice: Roy Rose

ITL have released their November Newsletter, Enjoy!

Key points of analysis, interview with Bill Mobbs CEO

In an encouraging start to the 05/06 financial year, ITL has increased its first quarter revenue by 26% when compared with the corresponding period last year.

We advise that the outcome of voting at ITL’s AGM on 27 October 2005 was as follows:

CEO Presentation for AGM 2005

Chairmans Address for AGM 2005

ITL has extended its long term relationship with the world’s largest blood banking organisation, the American Red Cross (ARC), for the supply of ITL’s range of patented safety and ergonomic blood coll

Notice of Change of Interest of Substantial Holder - Dr Jagmohanbir Dillon has lodged Form 604

30 June ITL Annual Report 2005

Mailing to Shareholders for ITL AGM 2005

Appendix 3B - New issue announcement, application for quotation of additional securities and agreement

Initial Director's Interest notice: Roy Rose

ITL is pleased to announce the appointment of Mr Roy Rose to the Board as a non- executive Director from the 1st of September 2005.

ITL is pleased to advise the full year results are stronger than the forecast, released in February 2005.

Full Year Report 12 Month Ended 30 June 2005

ITL is proud to announce that our Malaysian manufacturing facility has gained certification to the Environmental Management System ISO 14001:2004 and has also successfully upgraded our Quality Managem

Equity Capital Markets Limited press release on ITL's 2004-2005 performance and forecast.

ITL is pleased to advise that the un-audited second half results are stronger than the second half outlook, released in February 2005.

ITL wishes to advise the market of an updated guidance for our 2006 financial results.

Julian Gosse - Change of Director's Interest Notice

Macquarie Financial Services retains an Outperform recommendation on ITL.

ITL is pleased to release information about the Company’s recent performance. ITL is tracking in line with forecasts (issued February 2005) for the second half of financial year 04/05

ITL has signed a $6 million (AUD) contract to supply medical equipment to the prestigious Prince Court Medical Centre (PCMC) in Malaysia.

ITL has signed a $6 million (AUD) contract to supply medical equipment to the prestigious Prince Charles Medical Centre (PCMC) in Malaysia.

Bill Mobbs - Change of Director's Interest Notice

ITL was invited to present at the Citigroup Micro Caps Conference held in Sydney on Tuesday 4 April 2006. This was a great opportunity to showcase our company to over 100 business analysts and invest

Change of Director's Interest Notice - Richard England

Change of Director's Interest Notice - Julian Gosse

ITL CFO Susan Williams purchased 500,000 ordinary shares issued on 13 March 2006.

Changes to Bill Mobbs' company holdings.

Changes to Julian Gosse's company holdings.

The Australian Financial Review wrote today that ITL is one of the top 10 undervalued stocks. Reporter Trevor Hoey said that ITL was a ‘small firm with big potential.’ ITL was nominated by MMC Asset

Presented by Bill Mobbs, March 2005.

Interim result points to turnaround.

Half-yearly report - Six months ended 31 December 2004

ITL's Managing Director, Mr Bill Mobbs presented this PowerPoint presentation as a summary of ITL's first year as a public company and announced the way forward. Significant changes, review of current

Chairman’s address for Annual General Meeting, Tuesday, 30^th November 2004, Canberra

We advise that the outcome of voting at ITL’s AGM on 30 November 2004 was as follows

ITL has resolved its pending patent/licensing dispute with Fresenius/NPBI.

ITL has recently signed a major new contract with Australia’s largest private hospital operator, Affinity Health (formerly Mayne Health).

Bill Mobbs - Change of Director’s Interest Notice

Richard England - Change of Director’s Interest Notice

The ITL AGM proxy form can be downloaded as a pdf and mailed or faxed to ITL.

ITL has announced the 2004 Annual General Meeting. The meeting is scheduled for November 30 and will

ITL UK sales director David Laffar addresses the directors of the Russian and CIS blood service.

ITL Limited advises that 49,614,000 shares are today released from voluntary escrow.

ITL Limited Management Restructuring

Equity Capital Markets Limited: ITL Limited Management Restructuring

Joint managing director and co-founder of ITL, Dr Jag Dillon announced his resignation at the last I

Macquarie Financial Services: ITL Limited Management Changes

ITL Limited releases its first annual report. ITL Limited was first listed on the ASX in October of

ITL has accepted a $2.4 million dollar grant from the Federal government to develop next generation needle technology that will reduce the risk of needle stick injuries.